Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor.
作者信息
Fujino Toshio, Mitsudomi Tetsuya
机构信息
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
JTO Clin Res Rep. 2021 Mar 16;2(3):100134. doi: 10.1016/j.jtocrr.2020.100134. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor.MET酪氨酸激酶抑制剂的获得性耐药机制
JTO Clin Res Rep. 2021 Mar 16;2(3):100134. doi: 10.1016/j.jtocrr.2020.100134. eCollection 2021 Mar.
2
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.癌基因互换作为肺癌中获得性表皮生长因子受体-酪氨酸激酶抑制剂耐药的一种新机制。
Cancer Sci. 2016 Apr;107(4):461-8. doi: 10.1111/cas.12905. Epub 2016 Mar 28.
3
Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.在MET扩增的SNU-5胃异种移植瘤中，PI3K p110α的过表达导致对MET抑制剂产生获得性耐药。
Drug Des Devel Ther. 2015 Oct 19;9:5697-704. doi: 10.2147/DDDT.S89410. eCollection 2015.
4
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中 MET 外显子 14 跳跃导致对克唑替尼获得性耐药。
J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.
5
MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells.MET-Pyk2轴介导癌细胞对FGFR抑制的获得性耐药。
Front Oncol. 2021 Apr 7;11:633410. doi: 10.3389/fonc.2021.633410. eCollection 2021.
6
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.MET 和 KRAS 基因扩增介导对 MET 酪氨酸激酶抑制剂的获得性耐药。
Cancer Res. 2010 Oct 1;70(19):7580-90. doi: 10.1158/0008-5472.CAN-10-0436. Epub 2010 Sep 14.
7
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.趋同的Akt激活驱动肺癌中获得性表皮生长因子受体（EGFR）抑制剂耐药。
Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6.
8
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.MET 扩增型非小细胞肺癌细胞对 MET 抑制剂卡马替尼获得性耐药。
Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10.
9
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.在日本队列中，表皮生长因子受体突变型肺癌对酪氨酸激酶抑制剂的内在和获得性耐药中肝细胞生长因子的表达。
J Thorac Oncol. 2011 Dec;6(12):2011-7. doi: 10.1097/JTO.0b013e31823ab0dd.
10
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.多种受体酪氨酸激酶抑制剂和哺乳动物雷帕霉素靶蛋白抑制剂的联合应用通过抑制 c-Met 克服了肺癌细胞系对厄洛替尼的耐药性。
Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20.
引用本文的文献
1
A novel mesenchymal epithelial transition (MET) inhibitor, CB538, relieves acquired resistance in -mutated -amplified non-small cell lung cancer.一种新型间充质上皮转化（MET）抑制剂CB538可缓解EGFR突变、EGFR扩增的非小细胞肺癌中的获得性耐药。
Transl Cancer Res. 2025 Mar 30;14(3):1915-1927. doi: 10.21037/tcr-24-1614. Epub 2025 Mar 24.
2
Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.在罕见的TFG-MET融合晚期肺鳞状细胞癌中，通过抑制MET磷酸化对克唑替尼产生显著反应。
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae166.
3
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.评估 MET 和 AXL 抑制剂 Glesatinib（MGCD265）在非小细胞肺癌和其他晚期实体瘤患者中的 I 期研究。
Target Oncol. 2023 Jan;18(1):105-118. doi: 10.1007/s11523-022-00931-9. Epub 2022 Dec 2.
4
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic -Mutated, -Amplified NSCLC Patient With Acquired Y1230H Mutation.病例报告：一名转移性、MET突变且扩增的非小细胞肺癌（NSCLC）患者发生获得性Y1230H突变后，序贯联合使用I型和II型MET抑制剂进行靶向治疗
Front Oncol. 2021 Dec 2;11:738832. doi: 10.3389/fonc.2021.738832. eCollection 2021.
5
Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for -Amplified Tumors With -D1228X or -Y1230X Mutations.携带G1228X或Y1230X突变的MET扩增肿瘤对不同类别MET抑制剂的耐药和敏感差异模式。
JTO Clin Res Rep. 2021 Mar 16;2(3):100133. doi: 10.1016/j.jtocrr.2020.100133. eCollection 2021 Mar.
本文引用的文献
1
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by -D1228 and -Y1230 Mutations in -Mutated -Amplified Lung Cancer.在EGFR突变且扩增的肺癌中，奥希替尼联合赛沃替尼的获得性耐药由EGFR的D1228和Y1230突变介导。
JTO Clin Res Rep. 2020 Nov 1;1(4):100071. doi: 10.1016/j.jtocrr.2020.100071. Epub 2020 Jun 20.
2
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.患者 MET 外显子 14 突变型非小细胞肺癌中获得性对 MET 酪氨酸激酶抑制剂耐药的分子机制。
Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7.
3
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.肺癌中 MET 外显子 14 突变对 8 种 MET 酪氨酸激酶抑制剂的敏感性和耐药性的体外研究。
J Thorac Oncol. 2019 Oct;14(10):1753-1765. doi: 10.1016/j.jtho.2019.06.023. Epub 2019 Jul 3.
4
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.奥希替尼与卡博替尼联合治疗一名对克唑替尼耐药后出现多个MET二次位点突变的EGFR突变型肺腺癌患者
J Thorac Oncol. 2018 Apr;13(4):e49-e53. doi: 10.1016/j.jtho.2017.10.028. Epub 2017 Nov 8.
5
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.格来塞替尼在携带外显子 14 突变的肺癌模型和患者中显示出抗肿瘤活性，并克服了非临床模型中 I 型 MET 抑制剂突变介导的耐药性。
Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.
Zotero 插件